Compare AYTU & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AYTU | ABVC |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 26.1M |
| IPO Year | 2015 | 2009 |
| Metric | AYTU | ABVC |
|---|---|---|
| Price | $2.01 | $1.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.67 | N/A |
| AVG Volume (30 Days) | 40.1K | ★ 61.6K |
| Earning Date | 11-12-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.14 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,632,080.00 | $509,589.00 |
| Revenue This Year | $17.96 | N/A |
| Revenue Next Year | $27.98 | $171.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 277.47 | N/A |
| 52 Week Low | $1.80 | $0.71 |
| 52 Week High | $3.07 | $3.06 |
| Indicator | AYTU | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 50.97 |
| Support Level | $1.94 | $1.00 |
| Resistance Level | $2.34 | $1.14 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 48.55 | 61.69 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.